A detailed history of Teza Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Teza Capital Management LLC holds 10,044 shares of NBIX stock, worth $1.26 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
10,044
Previous 4,685 114.39%
Holding current value
$1.26 Million
Previous $646,000 113.93%
% of portfolio
0.17%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $701,278 - $767,355
5,359 Added 114.39%
10,044 $1.38 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $122,184 - $134,684
-937 Reduced 16.67%
4,685 $646,000
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $763,704 - $955,871
-7,200 Reduced 56.15%
5,622 $740,000
Q3 2023

Feb 22, 2024

BUY
$94.02 - $117.1 $293,060 - $365,000
3,117 Added 55.44%
8,739 $983,000
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $1.21 Million - $1.5 Million
12,822 New
12,822 $1.44 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $1.23 Million - $1.61 Million
-13,047 Reduced 83.15%
2,644 $267,000
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $1.18 Million - $1.4 Million
11,039 Added 237.3%
15,691 $1.87 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $428,123 - $501,532
4,652 New
4,652 $494,000
Q3 2020

Nov 12, 2020

SELL
$96.16 - $135.15 $627,636 - $882,124
-6,527 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$85.09 - $130.36 $233,657 - $357,968
2,746 Added 72.63%
6,527 $796,000
Q1 2020

May 11, 2020

BUY
$75.11 - $113.76 $60,238 - $91,235
802 Added 26.92%
3,781 $327,000
Q4 2019

Feb 12, 2020

BUY
$86.8 - $118.57 $258,577 - $353,220
2,979 New
2,979 $320,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Teza Capital Management LLC Portfolio

Follow Teza Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Teza Capital Management LLC with notifications on news.